[{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mateon Partners With Meridian IT to Fast Track Drug Manufacturing for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"Trabedersen","moa":"TGF beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Mateon Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mateon launches antiviral programme focused on Covid-19\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"OT-101","moa":"TGF beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mateon Therapeutics Team Publishes Article On The Positive Clinical Study Results For Ot-101 Against Recalcitrant Resistant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Trabedersen","moa":"TGF-beta 2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Mateon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mateon Achieves Milestone in its Development of OT-101, a Phase 3 Clinical Drug Candidate, Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Trabedersen","moa":"TGF beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mateon Announces the Filing of an IND with US FDA to Evaluate its Antisense Drug Candidate OT-101 in COVID-19 patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Trabedersen","moa":"TGF beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Autotelic BIO","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mateon Announces Achievement of Milestone Under Licensing of OT-101\/IL-2 Combination to Autotelic BIO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Trabedersen","moa":"TGF beta","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Autotelic BIO","highestDevelopmentStatusID":"4","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mateon and GMP to Proceed to Clinical Development of OT-101 and Artemisin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Trabedersen","moa":"TGF beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mateon is Selected by IBM Watson Health for the Use of IBM Clinical Development Solution for Phase II Clinical Trial of OT-101 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Trabedersen","moa":"TGF beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Mateon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mateon Therapeutics to Fund Observational Studies of Artemisinin in Developing Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Artemisinin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Mateon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mateon and Asili Research Alliance Enter Into Partnership for the Development of Artemisinin Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Artemisinin","moa":"TGF beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Mateon","highestDevelopmentStatusID":"4","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Granted Pediatric Disease Designation for OXi-4503","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Combretastatin A1 Diphosphate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mateon\u2019s Global Study for OT-101\/ Tgf-\u0392 Inhibitor Against Covid-19 Enrolls and Treats Its First Patient","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Trabedersen","moa":"TGF-beta 2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Oceanpine Capital","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Teon Therapeutics Completes $30 Million Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series A Financing","leadProduct":"TT-702","moa":"A2BR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mateon Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Oceanpine Capital","highestDevelopmentStatusID":"5","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Oncotelic","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mateon\u2019s Update on C001 - Global Study for Ot-101 Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Trabedersen","moa":"TGF-beta 2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mateon Therapeutics \/ Oncotelic","highestDevelopmentStatusID":"8","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Oncotelic Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncotelic Presenting Data for OT101 Against Pancreatic Cancer (PDAC) at the SITC 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Trabedersen","moa":"TGF beta-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mateon Therapeutics \/ Mateon Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Mateon The.."}]

Find Clinical Drug Pipeline Developments & Deals by Mateon Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Anti-viral activity OT-101 (trabedersen), in an in vitro antiviral testing which has a 50% effective concentration of 7.6 µg/mL and is not toxic at highest dose of 1000 µg/mL giving safety index value o...

                          Product Name : OT101

                          Product Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 28, 2022

                          Lead Product(s) : Trabedersen

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Oncotelic Therapeutics

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Mateon has completed the enrollment of its sentinel Part 1 and Part 2 COVID-19 patients which allows for the continuing expansion to the targeted 18 patients in part 1 and 18 patients in part 2. OT-101 is...

                          Product Name : OT-101

                          Product Type : Large molecule

                          Upfront Cash : Not Applicable

                          March 08, 2021

                          Lead Product(s) : Trabedersen,Artemisinin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Partner/Sponsor/Collaborator : Oncotelic

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Lead Product(s) : TT-702

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Partner/Sponsor/Collaborator : Oceanpine Capital

                          Deal Size : $30.0 million

                          Deal Type : Series A Financing

                          Details : The funds will be used to advance the company’s lead A2BR-selective antagonist TT-702 into the clinic as well as to build the company’s pipeline.

                          Product Name : TT-702

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 23, 2021

                          Lead Product(s) : TT-702

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Partner/Sponsor/Collaborator : Oceanpine Capital

                          Deal Size : $30.0 million

                          Deal Type : Series A Financing

                          blank

                          04

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : C-001 is a Phase 2 randomized, placebo-control study to evaluate safety and efficacy of OT-101 in combination with standard of care on two patient cohorts – 1) mild or moderate disease, and 2) severe di...

                          Product Name : OT-101

                          Product Type : Large molecule

                          Upfront Cash : Not Applicable

                          December 30, 2020

                          Lead Product(s) : Trabedersen,Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : OXi4503 in combination with standard chemotherapy drug cytarabine was generally well tolerated by adult AML patients and a maximum tolerated dose level of OXi4503 was identified as the recommended dose fo...

                          Product Name : OXi4503

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 16, 2020

                          Lead Product(s) : Combretastatin A1 Diphosphate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : ARTI19 is designed to rapidly establish the clinical efficacy of Artemisinin in mild and moderate COVID-19 patients. In-vitro, the medical grade version of the supplement has proven potency and safety sim...

                          Product Name : Undisclosed

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 20, 2020

                          Lead Product(s) : Artemisinin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Recipient : Asili Research Alliance

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          07

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Mateon Therapeutics announced that it will fund observational studies for Artemisinin, an herbal supplement, that demonstrated potent in vitro activity against SARS-CoV-2, the COVID-19 virus.

                          Product Name : Undisclosed

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 13, 2020

                          Lead Product(s) : Artemisinin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Recipient : Undisclosed

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          08

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Mateon was approved to use the platform following a review of the program as part of IBM Watson Health’s effort to help support and accelerate promising clinical COVID-19 candidates.

                          Product Name : OT-101

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          June 24, 2020

                          Lead Product(s) : Trabedersen

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Recipient : IBM Watson Health

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          09

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : GMP and Mateon are working to ensure safety and efficacy of OT-101 and Artemisinin for COVID-19 patients. OT-101 is an antisense against host TGF-β protein required for viral replication.

                          Product Name : OT-101

                          Product Type : Large molecule

                          Upfront Cash : Not Applicable

                          June 22, 2020

                          Lead Product(s) : Trabedersen

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : OT-101 has demonstrated robust efficacy against pancreatic cancer, glioblastoma, and melanoma during phase 2 clinical trials. The demonstration that OT-101 will synergize with IL-2 further demonstrate it...

                          Product Name : OT-101

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          June 10, 2020

                          Lead Product(s) : Trabedersen,Aldesleukin

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Partner/Sponsor/Collaborator : Autotelic BIO

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank